Corcept shareholders reject amended 2012 incentive plan at annual meeting

CORCEPT THERAPEUTICS INC

All nine director nominees elected, with votes ranging from 70.6M to 83.9M in favor.
Amended 2012 Incentive Award Plan not approved: 39.2M for, 44.6M against, 0.4M abstain.
Ratification of Ernst & Young as auditor for FY2022 approved with 96.4M votes for.

item 5.07

CORCEPT THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001628280-22-016073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.